Teleflex Announces Leadership Transition

Leadership Changes - Stuart Randle has been appointed as Interim President and CEO of Teleflex, succeeding Liam Kelly, who has departed from the company [1] - Dr. Stephen Klasko has been appointed as Chairman of the Board [1][2] - The Board has engaged Spencer Stuart to assist in the search for a permanent CEO [2] Business Strategy and Focus - Teleflex is transitioning to a more focused, higher-growth organization following the announced sale of its Acute Care, Interventional Urology, and OEM businesses [3] - The leadership transition is aimed at positioning the company for future growth in core critical care and high-acuity hospital markets [3] Financial Performance Update - The company expects full year 2025 revenue to be between $3.270 billion and $3.278 billion, a decrease from previous guidance of $3.305 billion to $3.320 billion [4] - The revenue reduction is primarily due to lower than expected demand for intra-aortic balloon pumps and catheters in the U.S. and Asia, as well as delays in OEM purchase orders [5] Future Reporting - Teleflex plans to report its full fourth quarter and full year 2025 financial results in late February or early March 2026 [7]